Zoetis Inc.: A Global Leader in Animal Health
Zoetis Inc. stands out as a formidable entity in the animal health sector, recognized for its extensive involvement in the discovery, development, manufacture, and marketing of veterinary vaccines and medicines. The company is headquartered in Parsippany, New Jersey, USA, and boasts operations in more than 100 countries worldwide.
Location and Facilities
Strategically dispersed across the globe, Zoetis' facilities include major research centers in the United States and significant production sites in Belgium and Brazil. Noteworthy among these is the Kalamazoo, Michigan facility, which is pivotal in producing Dectomax-CA1, a crucial product aimed at enhancing livestock health.
Financial Indicators
In 2022, Zoetis reported impressive financial metrics, with revenues reaching around $8.1 billion. The company's substantial market capitalization of approximately $80 billion reflects its robust market presence and the confidence it inspires among investors.
Important Company Events
A recent landmark event for Zoetis is the conditional approval of its avian influenza vaccine by the U.S. Department of Agriculture. This vaccine plays a crucial role in protecting poultry from the avian flu virus, a significant concern for poultry farmers and agricultural stability. This development highlights Zoetis' commitment to innovation and addressing emerging diseases in animal health.
Company Plans
Zoetis is poised to expand its product portfolio and fortify its standing in the veterinary vaccine market. The company is channeling investments into research and development to discover new solutions addressing global animal health challenges. A key focus is on expanding their vaccine offerings to combat various livestock diseases.
Additionally, Zoetis is advancing in the field of genetic partnerships, as exemplified by its collaboration with McCarty Family Farms and UNIFORM-Agri. These partnerships aim to enhance decision-making for dairy producers through genetic insights and herd management software, underscoring Zoetis' commitment to advancing the dairy industry.
Furthermore, Zoetis is actively involved in the dairy sector through the sponsorship of Dectomax CA-1, a drug approved for various types of dairy cattle, including lactating and dry cows, as well as replacement heifers aged 20 months and older. The company also supports the development of on-farm resources for U.S. dairy farmers by sponsoring manuals and pocket guides.
Eduardo Oliveira is a notable figure within Zoetis, serving as a director on the board of the Dairy Cattle Reproduction Council (DCRC), contributing to the company's influence in the dairy sector.
Modified: 2026/11/20
Related news
National Dairy Farmers Release 2026 Manual on Drug Residue Prevention
FDA Authorizes Emergency Use of Dectomax CA-1 for Dairy Cattle
Zoetis and UNIFORM-Agri Collaborate for Integrated Genetic Insights in Dairy Management
Genetic Advancements Propel U.S. Dairy Production by 70% to Meet Global Demand
FDA Conditionally Approves First Drug for Prevention and Treatment of New World Screwworm Infestations in Cattle
Trump Administration Shifts Strategy on Avian Flu